Jake Thornton retweeted
With Telfer generating substantial cash flow and Havieron now under construction, Greatland is positioning itself to become one of Australia's leading gold producers.
Another great step forward on the science front for #avct displaying their expanding platform pipeline
It’s increasingly clear why the market is unable to grasp what the co is potentially sat on. It’s incredibly complex stuff.
Really hope this is converted on the business front
Avacta will present AVA6207, its Next-Generation pre|CISION® dual payload peptide-drug conjugate, in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18-20. avacta.com/avacta-to-present… #AVCT
Agreed #ggp been unfairly smashed in line with gold decline. No value given to fundamentals.
Copper playing its part this quarter too.
A 25m cash build with 5mths of tax instalments accounted for and no slow in Hav or Telfer development is impressive indeed!
Superb start to FY27 considering the current macro.
Great result from the team that always seem to deliver 👏👏👏
Still increasing cash build whilst building Havieron and investing in Telfer
announcements.asx.com.au/asx…
#GGP $GGP @Greatland_GGP #Telfer #Havieron
2
10
418
#AVCT so:
- It works
- Safe
- Pre clinical translates into humans in clinic
- Consistency across 6000 and 6103
- Unique finding to potentially seal the USP vs ADCs
And so much more to come. Surely momentum builds from here!?
#avct
Absolutely - if the platform can show it creates a feedback loop where it is able to switch on its own delivery mechanism even in tumors with very low FAP expression this is huge
This is the best part of the RNS
#avct ❤️🥇 incredible:
‘Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment
1/2
#GGP
Hopefully there is a catalyst for the SP ahead of this otherwise the excitement may well be tamed compared to others.
SP capitulation isn’t pretty.
Can’t help but think gold price drop has left nothing to should about re Q3 finances so have skipped the prelim update.
Expecting to be in London for December 2026 town hall function, which will cap off a significant year for #Greatland, but still much to be done.
#GGP
217
#ggp
Whilst I know gold is getting a good hiding it’s painful to see GGP back at these levels…..and wondering why the delay in quarterly production update @shaun_day_
1
183
#avct their thought process is clear - maximise the upside by enhancing the data, but that does come at a cost….as does everything. They do however need to ensure that is executed properly and minimise that cost
Replying to @BigBiteNow @NstaM0
I think you’ve hit the nail on the head here BBN. It’s a classic #avct storm in a teacup…funding was always needed it’s not a surprise. It’s now the manner in how they do it and how much that will tell the story.
11
1,905
Think they’ve missed the point. In rare cancers like SGC, requiring OS can make studies much larger and slower. A single pivotal trial using PFS is a materially easier path than a large OS-driven program. Big step.
BP will also happily pay more for #avct doing derisking for then
Replying to @YorkshirPuddin
Great point Jake.
There is a lot of ‘bed wetting’ on LSE this morning. Why not partner yet! Must be traders.
CC continues to build a very strong case for a very rosy future for the patient shareholders.
Well done CC
1
28
2,581
Unlike most markets, biotech has exponential upside but also downside can be catastrophic and happen instantly.
BP would happily let #avct do the derisking giving up a little bit of the huge upside to limit the downside. (To a point as they also don’t want to leave it too late)
15
1,823
#avct
Let that sink in for a minute.
Validate the platform and the world is your oyster in terms of target/applicable market!
Add to that the FDA has agreed to a pivotal study with PFS as the sole primary endpoint rather than OS, implying they believe PFS is a clinically meaningful endpoint and #avct existing data is sufficiently encouraging to justify a registrational strategy built around it.
#avct
Well well well….the pivotal P2 study that so many haters in the past said would never happen and P3 was a necessity!
It was clear the FDA relationship was strengthening and this shows they see enough in AVA6000 to progress.
🙌
#avct
Well well well….the pivotal P2 study that so many haters in the past said would never happen and P3 was a necessity!
It was clear the FDA relationship was strengthening and this shows they see enough in AVA6000 to progress.
🙌
Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer. avacta.com/avacta-announces-… #AVCT
😂 sadly I couldn’t attend the PTCLND meetings as I was still in the middle of a 2021 PTLFT meeting that Alastair had said was finishing “soon”
#AVCT
What a turnaround indeed!
Replying to @hughesy0707 @coughlin582
“What a difference a year makes.”
Congratulations to Chris and the Zeus team.
A year ago the conversation was dominated by the CLN. Today it feels as though it is being proactively managed rather than managing us.
Shareholders are recovering well from PTCLND (Post-Traumatic CLN Disorder).
Looking forward to the next chapter.
#AVCT
#avct
If this is being hailed a “game changer” for reducing sickness and hair loss. Just wait until Avactas precision tech comes to market. Think it will be extending lives well beyond an extra 4 months!
bbc.co.uk/news/articles/ce8p…
#avct for so long had scientists doing business level board room work and have always lacked a cutthroat business person to execute it….until now.
RH is that out and out business man. They’re adding biotech expertise to support him and have CC leading the science/tech.
A-team!
Replying to @BobDibble8
Of course, and the company have been fairly explicit on that. You have to give up something to maximise the upside. I guess my point here is that for the first time I feel like #avct knows it’s worth and how to maximise value. With finally the right people to execute!
#avct
The more of these deals you see involving pre clinical assets cements for me that Avacta know exactly what they’re sat on and are barricading the door until max value and the right partner is found. They won’t give it away. RH is the man to steer this ship!
$650m upfront, possible $10bn total.
Eight early-stage Innovent assets and four Pfizer-proposed discovery programmes, including antibody-drug conjugates (ADCs) with unique payloads.
Nothing yet at clinical stage.
There's money around.
#AVCT
firstwordpharma.com/story/74…
#avct
Here we go! Been a long time coming to get rid of that useless chairman!
RH to take this to the next level alongside CC 🙌
#GGP
Explains the recent price action. Nothing related to fundamentals….think we press on from here waiting for Havieron FID in the next couple of weeks
405




















